Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 28, 1998

View Archived Issues

Company Profile: Nymox

Major innovations fuel R&D at Astra

Agents for chronobiological disorders synthesized at Glaxo

PKC modulators for proliferative disorders described by Georgetown U.

New AIDS therapies in development in Korea

Indole endothelin antagonists prepared at Pfizer

Antitumor and antiviral distamycin derivatives from Pharmacia & Upjohn

Flavopiridol analogues as inhibitors of cyclin-dependent kinases

BMS discloses new Taxol derivative

Phenylglycine derivatives with mGluR-antagonist activity disclosed by Lilly

Positive U.S. phase II results for Thymoglobulin in preventing kidney transplant rejection

Anti-TNF strategy in MS treatment should be reconsidered

Rate-independent profile of antiarrhythmic agent suggests improved therapeutic potential

BioMarin's lead enzyme replacement therapy enters clinical trials

New test for cardiovascular disease risk assessment from Myriad Genetics

FDA panel recommends approval of Verdia

In vivo efficacy reported for angiotensin II blocker

EUK-134 effective in animal model of stroke

Allelix: Q1 1998 highlights

Antihypertensive efficacy described for Novartis' dual ACE/NEP inhibitor

Phase II trials of Sibia's Parkinson's disease Rx begin

Japanese approval for Biora's periodontal disease product

Pacific's cancer immunotherapy proves highly effective in rat metastatic mammary tumor model

Vaccine delivery joint venture finalized by Endorex and Elan

Viragen seeks to become fully integrated blood products company

ACT evaluated in second phase I trial in HIV/AIDS patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...